Mouth UlcerDERMAL-LRNCT06969495
Pilot Clinical Study Testing Tiger Milk Mushroom Gel (Lignosus Rhinocerus TM02®) for Treating Mouth Ulcers
A study testing xLr oral gel and Kanolone in people with Mouth Ulcer, run by Mahsa University at 1 site in Malaysia.
Trial summary
This is a pilot clinical trial study to investigate the wound healing capability of a TM02® water extract formulation in patient with minor oral ulcers (2 - 5 mm in size). The sclerotium of L. Read more about this study
- Who is it for?
- Ages 20 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Mouth Ulcer
- What is being tested?
- xLr oral gel and Kanolone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 21 participants
- Where
- 1 siteMalaysia
- Study dates
- 1 Feb 2023to 23 Feb 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male and female participants aged between 20 and 50 years
- No history of systemic diseases such as leukemia, hemophilia, uncontrolled diabetes mellitus, or serious cardiac conditions
- Presence of minor oral aphthous ulcers ranging from 2 to 5 mm in size
- No use of medications, including topical steroids or mouthwashes, for at least 3 months prior to the study
- Willingness to provide written informed consent and adhere to the study protocol.
Who cannot join
- Pregnant or lactating women; Known allergies to any components of the study formulations
- Any condition that, in the opinion of the investigator, may interfere with the study objectives or participant safety.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Clinical Investigation Into the Dermal Application of L. Rhinocerus TM02(r) Water Extract for Mouth Ulceration
This is a pilot clinical trial study to investigate the wound healing capability of a TM02® water extract formulation in patient with minor oral ulcers (2 - 5 mm in size). The sclerotium of L. rhinocerus is traditionally used as a health tonic or treatment regime for asthma, bronchitis, various cancer ailments as well as discomforts caused by fright, fever, cough, vomiting, and injury. Further on to that, this mushroom has also been traditionally used by the local Malay and Chinese communities to treat wounds, although it is yet to be scientifically validated. Its sclerotia are being consumed in the form of decoction, in a betel quid, and other preparation method where the sclerotium is pounded with raw rice, infused, and subsequently taken as a drink. There is also a practice of biting/chewing of the sclerotium by local indigenous communities during their journeys in the wild.
Read the detailed description
Project overview Lignosus rhinocerus, commonly known as tiger milk mushroom (TMM), is a medicinal fungus native to Southeast Asia. Traditionally, it has been utilized for various health conditions, including wound healing. Recent studies have highlighted its anti-inflammatory, antimicrobial, and immunomodulatory properties, particularly in its cultivated form, TM02® .
Aphthous ulcers, or recurrent aphthous stomatitis (RAS), are common, painful lesions of the oral mucosa affecting a significant portion of the adult population. Current treatments primarily involve topical corticosteroids, which may have side effects with prolonged use. Given the traditional use of L. rhinocerus in wound care, this study aims to evaluate the efficacy of TM02® gel in treating minor oral aphthous ulcers.
Hypothesis and general objective Hypothesis: L. rhinocerus cultivar TM02® gel accelerates the healing process of minor oral aphthous ulcers compared to standard treatments.
Primary Objective: To assess the efficacy of L. rhinocerus TM02® gel in promoting the healing of minor oral aphthous ulcers.
Methodology Mushroom Material and Gel Formulation Lignosus rhinocerus TM02® freeze-dried sclerotia powder (TM02®) was obtained from LiGNO Biotech Sdn. Bhd. (Selangor, Malaysia). This commercially available product is officially registered under the Protection of New Plant Varieties Act (NPVA), Malaysia (Registration No.: PVBT010/11). The authenticity of TM02® was confirmed via polymerase chain reaction (PCR) amplification and sequencing of the internal transcribed spacer (ITS) region. To extract its bioactive compounds, the sclerotia powder underwent cold water extraction at a 1:20 ratio of powder to distilled water, followed by centrifugation and freeze-drying. The resulting extract, referred to as xLr®, was then formulated into an oral gel by incorporating it with xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative. The final gel formulation (containing 25% xLr®) was stored at room temperature until further use.
Study Design and Ethical Approval A double-blinded, randomised clinical trial was conducted with approval from the Research Management Centre, MAHSA University (Ethics No.: RMC/EC45/2022). Prior to enrolment, all participants received a patient information sheet detailing the study objectives, procedures, potential risks, and benefits. Informed consent was obtained from each participant before proceeding. Systemically healthy patients presenting with minor, isolated aphthous ulcers were recruited, while individuals taking medication, using mouthwash, or consuming herbal products were excluded. A third party managed the randomisation process to ensure impartiality, and both investigators and participants remained blinded to the assigned treatments. For participants with language barriers, a student translator assisted in explaining the study details and consent process to ensure clear communication. All study procedures were conducted in accordance with ethical guidelines and clinical protocols.
Treatment Protocol A total of 21 patients (8 males, 13 females), aged 20-50 years, were randomly allocated into three groups. The control group received the base formulation without xLr®, the test group received the xLr® oral gel, and the standard treatment group was given Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%). Patients were instructed to apply a thin layer of the assigned gel to the ulcer using a dry cotton bud three times daily for seven days, ensuring no eating or drinking for at least 30 minutes post-application.
Clinical Evaluations Pain levels were recorded daily for seven days using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain). Ulcer size was measured on Days 1, 3, 5, and 7 using a transparent grid overlay. Each square on the grid represented a surface area of 4 mm². The total ulcer area (mm²) was determined by counting the number of squares within the ulcer's outline, providing an objective assessment of wound size over time. Wound epithelialisation was assessed on Days 3, 5, and 7 by applying a 3% hydrogen peroxide (H₂O₂) solution to the ulcer site. Bubble formation indicated incomplete epithelialisation, whereas the absence of bubbles signified complete epithelialisation, providing a clear and reliable measure of the healing process over time. For cases where epithelialisation required more than seven days-exceeding the study's observation period-it was assigned a value of 8 for analytical consistency.
Study Site The trial was conducted at MAHSA University's clinical facilities, specifically within the Faculty of Dentistry.
- Conditions
- Mouth Ulcer
- Being tested
- xLr oral gel, Placebo, Kanolone
- Keywords
- Tiger Milk Mushroom, Mouth ulcers, Wound healing, Natural remedies
- Medical subject headings
- Oral Ulcer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
xLr oral gelOther
Also called TM02 gel
25% of Cold water extract of Tiger milk mushroom sclerotial powder in a gel form containing xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative.
PlaceboOther
Also called Vehicle ctrl
oral gel base formulation without the Lignosus rhinocerus extract
KanoloneDrug
Also called Positive ctrl
Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%)
| Study group | Role | What they receive |
|---|---|---|
| Base formulation | Placebo comparator | Participants will receive an oral gel base formulation without the Lignosus rhinocerus extract. The placebo gel will be applied to the mouth ulcer three times daily for seven days. Receives: Other: Placebo |
| xLr oral gel | Experimental | Participants will receive an oral gel containing 25% Lignosus rhinocerus TM02® cold water extract (xLr®). The gel will be applied to the mouth ulcer three times daily for seven days. Receives: Other: xLr oral gel |
| Kanolone Oral Base Paste | Active comparator | Participants will receive Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%), a standard topical corticosteroid treatment for aphthous ulcers. The paste will be applied to the mouth ulcer three times daily for seven days. Receives: Drug: Kanolone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Assessment
Pain levels were assessed daily over a seven-day period using the Visual Analog Scale (VAS), where 0 represented no pain and 10 indicated the worst possible pain.
Measured: Daily assessments on Days 1 through 7 during the intervention
Wound Epithelialization
Wound epithelialisation was evaluated on Days 3, 5, and 7 by applying a 3% hydrogen peroxide (H₂O₂) solution to the ulcer site. The formation of bubbles indicated incomplete epithelialisation, while the absence of bubbles signified complete epithelialisation, offering a reliable and consistent measure of the healing process.
Measured: Assessments on Days 3, 5, and 7 during the intervention
Ulcer size
Ulcer size was measured on Days 1, 3, 5, and 7 using a transparent grid overlay. Each square on the grid represented a surface area of 4 mm². The total ulcer area (mm²) was determined by counting the number of squares within the ulcer's outline, providing an objective assessment of wound size over time
Measured: Days 1, 3, 5, and 7 during the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2025
- Study start1 Feb 2023
- Primary completion30 Nov 2023
- Study completion23 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mouth UlcerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mahsa University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yeannie Yap, Mahsa University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06969495
- Sponsor's protocol ID
- RP185_05/22
- Acronym
- DERMAL-LR
- Status last verified
- May 2025
- First submitted
- 28 Apr 2025
- Last updated
- 15 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Investigation Into the Dermal Application of L. Rhinocerus TM02(r) Water Extract for Mouth Ulceration
- ClinicalTrials.gov ID
- NCT06969495
- Acronym / sponsor ID
- DERMAL-LR / RP185_05/22
- Conditions
- Mouth Ulcer
- Keywords
- Tiger Milk Mushroom, Mouth ulcers, Wound healing, Natural remedies
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Mahsa UniversityUniversity, hospital or other
- Study start
- 1 Feb 2023 (actual)
- Primary completion
- 30 Nov 2023 (actual)
- Study completion
- 23 Feb 2024 (actual)
- First posted
- 14 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pilot clinical trial study to investigate the wound healing capability of a TM02® water extract formulation in patient with minor oral ulcers (2 - 5 mm in size). The sclerotium of L. rhinocerus is traditionally used as a health tonic or treatment regime for asthma, bronchitis, various cancer ailments as well as discomforts caused by fright, fever, cough, vomiting, and injury. Further on to that, this mushroom has also been traditionally used by the local Malay and Chinese communities to treat wounds, although it is yet to be scientifically validated. Its sclerotia are being consumed in the form of decoction, in a betel quid, and other preparation method where the sclerotium is pounded with raw rice, infused, and subsequently taken as a drink. There is also a practice of biting/chewing of the sclerotium by local indigenous communities during their journeys in the wild.
Detailed description
Project overview Lignosus rhinocerus, commonly known as tiger milk mushroom (TMM), is a medicinal fungus native to Southeast Asia. Traditionally, it has been utilized for various health conditions, including wound healing. Recent studies have highlighted its anti-inflammatory, antimicrobial, and immunomodulatory properties, particularly in its cultivated form, TM02® .
Aphthous ulcers, or recurrent aphthous stomatitis (RAS), are common, painful lesions of the oral mucosa affecting a significant portion of the adult population. Current treatments primarily involve topical corticosteroids, which may have side effects with prolonged use. Given the traditional use of L. rhinocerus in wound care, this study aims to evaluate the efficacy of TM02® gel in treating minor oral aphthous ulcers.
Hypothesis and general objective Hypothesis: L. rhinocerus cultivar TM02® gel accelerates the healing process of minor oral aphthous ulcers compared to standard treatments.
Primary Objective: To assess the efficacy of L. rhinocerus TM02® gel in promoting the healing of minor oral aphthous ulcers.
Methodology Mushroom Material and Gel Formulation Lignosus rhinocerus TM02® freeze-dried sclerotia powder (TM02®) was obtained from LiGNO Biotech Sdn. Bhd. (Selangor, Malaysia). This commercially available product is officially registered under the Protection of New Plant Varieties Act (NPVA), Malaysia (Registration No.: PVBT010/11). The authenticity of TM02® was confirmed via polymerase chain reaction (PCR) amplification and sequencing of the internal transcribed spacer (ITS) region. To extract its bioactive compounds, the sclerotia powder underwent cold water extraction at a 1:20 ratio of powder to distilled water, followed by centrifugation and freeze-drying. The resulting extract, referred to as xLr®, was then formulated into an oral gel by incorporating it with xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative. The final gel formulation (containing 25% xLr®) was stored at room temperature until further use.
Study Design and Ethical Approval A double-blinded, randomised clinical trial was conducted with approval from the Research Management Centre, MAHSA University (Ethics No.: RMC/EC45/2022). Prior to enrolment, all participants received a patient information sheet detailing the study objectives, procedures, potential risks, and benefits. Informed consent was obtained from each participant before proceeding. Systemically healthy patients presenting with minor, isolated aphthous ulcers were recruited, while individuals taking medication, using mouthwash, or consuming herbal products were excluded. A third party managed the randomisation process to ensure impartiality, and both investigators and participants remained blinded to the assigned treatments. For participants with language barriers, a student translator assisted in explaining the study details and consent process to ensure clear communication. All study procedures were conducted in accordance with ethical guidelines and clinical protocols.
Treatment Protocol A total of 21 patients (8 males, 13 females), aged 20-50 years, were randomly allocated into three groups. The control group received the base formulation without xLr®, the test group received the xLr® oral gel, and the standard treatment group was given Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%). Patients were instructed to apply a thin layer of the assigned gel to the ulcer using a dry cotton bud three times daily for seven days, ensuring no eating or drinking for at least 30 minutes post-application.
Clinical Evaluations Pain levels were recorded daily for seven days using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain). Ulcer size was measured on Days 1, 3, 5, and 7 using a transparent grid overlay. Each square on the grid represented a surface area of 4 mm². The total ulcer area (mm²) was determined by counting the number of squares within the ulcer's outline, providing an objective assessment of wound size over time. Wound epithelialisation was assessed on Days 3, 5, and 7 by applying a 3% hydrogen peroxide (H₂O₂) solution to the ulcer site. Bubble formation indicated incomplete epithelialisation, whereas the absence of bubbles signified complete epithelialisation, providing a clear and reliable measure of the healing process over time. For cases where epithelialisation required more than seven days-exceeding the study's observation period-it was assigned a value of 8 for analytical consistency.
Study Site The trial was conducted at MAHSA University's clinical facilities, specifically within the Faculty of Dentistry.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Base formulation | Placebo comparator | Other: PlaceboParticipants will receive an oral gel base formulation without the Lignosus rhinocerus extract. The placebo gel will be applied to the mouth ulcer three times daily for seven days. |
| xLr oral gel | Experimental | Other: xLr oral gelParticipants will receive an oral gel containing 25% Lignosus rhinocerus TM02® cold water extract (xLr®). The gel will be applied to the mouth ulcer three times daily for seven days. |
| Kanolone Oral Base Paste | Active comparator | Drug: KanoloneParticipants will receive Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%), a standard topical corticosteroid treatment for aphthous ulcers. The paste will be applied to the mouth ulcer three times daily for seven days. |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Male and female participants aged between 20 and 50 years
- No history of systemic diseases such as leukemia, hemophilia, uncontrolled diabetes mellitus, or serious cardiac conditions
- Presence of minor oral aphthous ulcers ranging from 2 to 5 mm in size
- No use of medications, including topical steroids or mouthwashes, for at least 3 months prior to the study
- Willingness to provide written informed consent and adhere to the study protocol.
Key exclusion criteria (2 listed)
- Pregnant or lactating women; Known allergies to any components of the study formulations
- Any condition that, in the opinion of the investigator, may interfere with the study objectives or participant safety.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| xLr oral gelAlso: TM02 gel25% of Cold water extract of Tiger milk mushroom sclerotial powder in a gel form containing xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative. | Other | xLr oral gel |
| PlaceboAlso: Vehicle ctrloral gel base formulation without the Lignosus rhinocerus extract | Other | Base formulation |
| KanoloneAlso: Positive ctrlKanolone Oral Base Paste (Triamcinolone acetonide 0.1%) | Drug | Kanolone Oral Base Paste |
Primary outcome
Pain Assessment
Time frame: Daily assessments on Days 1 through 7 during the intervention
Pain levels were assessed daily over a seven-day period using the Visual Analog Scale (VAS), where 0 represented no pain and 10 indicated the worst possible pain.
Wound Epithelialization
Time frame: Assessments on Days 3, 5, and 7 during the intervention
Wound epithelialisation was evaluated on Days 3, 5, and 7 by applying a 3% hydrogen peroxide (H₂O₂) solution to the ulcer site. The formation of bubbles indicated incomplete epithelialisation, while the absence of bubbles signified complete epithelialisation, offering a reliable and consistent measure of the healing process.
Ulcer size
Time frame: Days 1, 3, 5, and 7 during the intervention
Ulcer size was measured on Days 1, 3, 5, and 7 using a transparent grid overlay. Each square on the grid represented a surface area of 4 mm². The total ulcer area (mm²) was determined by counting the number of squares within the ulcer's outline, providing an objective assessment of wound size over time
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2025.
- Individual participant dataSharing planned: No
Related trials for Mouth Ulcer
RecruitingObservational study
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease
RecruitingPhase 3
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Behçet's Disease, Juvenile Psoriatic Arthritis
RecruitingPhase 1/2
Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Not yet recruitingPhase 1
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation
Psoriasis, Arthritis, Psoriatic
RecruitingPhase 2
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing xLr oral gel and Kanolone in people with Mouth Ulcer, run by Mahsa University at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Assessment (time frame: Daily assessments on Days 1 through 7 during the intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.